Phosphoinositide 3-kinase inhibitors in lymphoma

Current Opinion in Oncology

Volumn 26, Issue 5, 2014, Pages 469-475

  Curran, Emily ^a   Smith, Sonali M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

chronic lymphocytic leukemia; indolent non Hodgkin lymphoma; mantle cell lymphoma; phosphoinositide 3 kinase inhibitors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMG 319; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BORTEZOMIB; BUPARLISIB; CHLORAMBUCIL; DUVELISIB; EVEROLIMUS; FLUDARABINE; GS 9973; IDELALISIB; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; OBINUTUZUMAB; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RITUXIMAB; TGR 1202; UBLITUXIMAB; UNCLASSIFIED DRUG; WORTMANNIN; PROTEIN KINASE INHIBITOR;

ABNORMAL LABORATORY RESULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; CYTOPATHOGENIC EFFECT; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTRANSAMINASEMIA; LIVER TOXICITY; LYMPHATIC LEUKEMIA; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSEUDOMONAS INFECTION; RASH; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYMOLOGY; METABOLISM;

HUMANS; LYMPHOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS;

EID: 84906079318     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000113     Document Type: Review

References (47)

1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Can 2002; 2: 489-501
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619
3. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-1083
4. Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22: 686-707
5. McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708-722
6. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta,-gamma, and-delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006; 103: 1289-1294
7. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554
8. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3: 1221-1224
9. Fruman DA, Rommel C. PI3Kd inhibitors in cancer: Rationale and serendipity merge in the clinic. Cancer Discov 2011; 1: 562-572
10. Chantry D, Vojtek A, Kashishian A, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997; 272: 19236-19241
11. Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 1997; 94: 4330-4335
12. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001; 98: 3050-3057
13. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92
14. Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004; 45: 2365-2372
15. Rosich L, Saborit-Villarroya I, Lopez-Guerra M, et al. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica 2013; 98: 1739-1747
16. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-120
17. Durand CA, Hartvigsen K, Fogelstrand L, et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 2009; 183: 5673-5684
18. Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002; 22: 8580-8591
19. Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002; 297: 1031-1034
20. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008; 27: 5511-5526
21. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-594
22. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-2088
23. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612
24. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390-3397
25. Sharman J, de Vos S, Leonard J, et al. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). San Diego, California, USA: American Society of Hematology; 2011 (in press
26. Coutre S, Leonard J, Furman R, et al. Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a phase I study. Atlanta, Georgia, USA: American Society of Hematology; 2012
27. Barrientos JC, Furman RR, Leonard J, et al. Update on a phase I study of the selective PI3K-delta inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. Chicago, Illinois, USA: American Society of Clinical Oncology; 2013
28. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007
29. De Vos S, Leonard JP, Barrientos JC, et al. A phase 1 study of the selective PI3Kd inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia. New Orleans, Los Angeles, USA: American Society of Hematology; 2013
30. Flinn I, Kimby E, Cotter FE, et al. A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL). Chicago, Illinois: American Society of Oncology Annual Meeting; 2013
31. Herman SE, Lapalombella R, Gordon AL, et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011; 117: 4323-4327
32. Coutre S, Byrd J, Furman R, et al. Phase I study of CAL-101, an isoformselective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. Chicago, Illinois, USA: American Society of Clinical Oncology; 2011
33. Brown J, Furman R, Flinn I, et al. Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kd, in patients with relapsed or refractory CLL. Chicago, Illinois, USA: American Society of Clinical Oncology; 2013
34. Patel M, Kahl BS, Horwitz SM, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-d, g, in patients with chronic lymphocytic leukemia. New Orleans, Los Angeles, USA: American Society of Hematology; 2013
35. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123: 3406-3413
36. Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008-1018
37. Leonard J, Wagner-Johnston N, Coutre S, et al. Tolerability and activity of combinations of the PI3Kd inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. Chicago, Illinois, USA: American Society of Clinical Oncology; 2013
38. Horwitz S, Flinn I, Patel M, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-d, g, in patients with relapsed/ refractory lymphoma. Chicago, Illinois, USA: American Society of Clinical Oncology; 2013
39. Rizzatti EG, Falcao RP, Panepucci RA, et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 2005; 130: 516-526
40. Dal Col J, Zancai P, Terrin L, et al. Distinct functional significance of Akt and mTORconstitutive activation inmantle cell lymphoma. Blood2008;111: 5142-5151
41. Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398-3405
42. Wagner-Johnston N, De Vos S, Leonard J, et al. Preliminary results of PI3Kd inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). Chicago, Illinois, USA: American Society of Clinical Oncology; 2013
43. Meadows SA, Vega F, Kashishian A, et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012; 119: 1897-1900
44. Horwitz S, Younes A, Flinn I, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta, gamma, in patients with relapsed/refractory T-cell lymphoma International Conference on Malignant Lymphoma; 2013; Lugano, Switzerland
45. Herko A, Mavis M, Czuczman M, Hernandez F. AMG 319, a novel inhibitor of phosphoinositide-3 kinase delta (PI3Kd), demonstrates activity in lymphoma pre-clinical models. Atlanta, Georgia, USA: American Society of Hematology; 2012
46. Savona M, Gutierrez M, Lanasa M, et al. A phase I dose escalation study of TGR-1202, a novel PI3K-d inhibitor, for patients with relapsed or refractory hematologic malignancies. New Orleans, Los Angeles, USA: American Society of Hematology; 2013
47. Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012; 11: 317-328